Search results
Showing 301 to 315 of 1259 results for pathway
Digitally enabled therapies for adults with anxiety disorders: early value assessment (HTG676)
Early value assessment (EVA) guidance on digitally enabled therapies for adults with anxiety disorders.
This quality standard covers adults with rehabilitation needs as a result of critical illness that required level 2 or level 3 critical care. It describes high-quality care in priority areas for improvement.
View quality statements for QS158Show all sections
NICE has developed a medtech innovation briefing (MIB) on OrganOx metra for liver transplant .
FibroScan for assessing liver fibrosis and cirrhosis outside secondary and specialist care (HTG682)
Evidence-based recommendations on FibroScan for assessing liver fibrosis and cirrhosis outside secondary and specialist care.
Evidence-based recommendations on multiplex allergen testing, using ImmunoCAP ISAC 112 in people with allergy that is difficult to diagnose.
This quality standard covers health and social care services for adults, young people and children with autism. It includes assessment and diagnosis of autism spectrum disorders, and care and support for people diagnosed with an autism spectrum disorder. It describes high-quality care in priority areas for improvement.
View quality statements for QS51Show all sections
Sections for QS51
- Quality statements
- Quality statement 1: Diagnostic assessment by an autism team
- Quality statement 2: Assessment and diagnosis
- Quality statement 3: Personalised plan
- Quality statement 4: Coordination of care and support
- Quality statement 5: Treating the core features of autism: psychosocial interventions
- Quality statement 6: Treating the core features of autism: medication
- Quality statement 7: Assessing possible triggers for behaviour that challenges
Dapagliflozin for treating chronic heart failure with reduced ejection fraction (TA679)
Evidence-based recommendations on dapagliflozin (Forxiga) for symptomatic chronic heart failure with reduced ejection fraction in adults.
Evidence-based recommendations on vadadustat (Vafseo) for treating symptomatic anaemia in adults having dialysis for chronic kidney disease.
Cannabidiol with clobazam for treating seizures associated with Lennox–Gastaut syndrome (TA615)
Evidence-based recommendations on cannabidiol (Epidyolex) with clobazam for seizures associated with Lennox–Gastaut syndrome in people aged 2 years and older.
Evidence-based recommendations on olaparib (Lynparza) for previously treated BRCA mutation-positive hormone-relapsed metastatic prostate cancer in adults.
Digital technologies to support self-management of COPD: early value assessment (HTG736)
Early value assessment (EVA) guidance on digital technologies to support self-management of COPD.
DMD Care UK's guideline on respiratory care: NICE review (NR2)
NICE has reviewed DMD Care UK’s guideline on respiratory care for Duchenne muscular dystrophy. We think the guideline from DMD Care UK is a useful resource that will help healthcare professionals improve care in this area
NICE has developed a medtech innovation briefing (MIB) on point-of-care and home faecal calprotectin tests for monitoring treatment response in inflammatory bowel disease .
Alitretinoin for the treatment of severe chronic hand eczema (TA177)
Evidence-based recommendations on alitretinoin (Toctino) for treating severe chronic hand eczema in adults.
Trametinib in combination with dabrafenib for treating unresectable or metastatic melanoma (TA396)
Evidence-based recommendations on trametinib (Mekinist) with dabrafenib (Tafinlar) for adults with unresectable or metastatic melanoma that has a BRAF V600 mutation.